COLLABORATION AND LICENSE AGREEMENT between LEXICON GENETICS INCORPORATED and BRISTOL-MYERS SQUIBB COMPANYCollaboration and License Agreement • May 5th, 2015 • Lexicon Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
This Collaboration and License Agreement (this “Agreement”) is dated as of December 17, 2003 (the “Effective Date”) and is made by and between Lexicon Genetics Incorporated, a Delaware corporation (“Lexicon”), and Bristol-Myers Squibb Company, a Delaware corporation (“BMS”). Lexicon and BMS are sometimes referred to herein individually as a “party” and collectively as the “parties.”
First Amendment to Collaboration and License AgreementCollaboration and License Agreement • May 5th, 2015 • Lexicon Pharmaceuticals, Inc. • Pharmaceutical preparations
This First Amendment to Collaboration and License Agreement (the “Amendment”) is entered into effective as of the last date set forth on the signature page hereof (the “Effective Date”) by and between Lexicon Genetics Incorporated, a Delaware corporation (“Lexicon”) and Bristol-Myers Squibb Company, a Delaware corporation (“BMS”).
FIRST AMENDMENT TO LICENSE AND COLLABORATION AGREEMENTLicense and Collaboration Agreement • May 5th, 2015 • Lexicon Pharmaceuticals, Inc. • Pharmaceutical preparations
This First Amendment to License and Collaboration Agreement (the “Amendment”) is entered into effective as of the last date set forth on the signature page hereof (the “Amendment Effective Date”) by and between LEXICON PHARMACEUTICALS, INC., a Delaware corporation with its principal offices at 8800 Technology Forest Place, The Woodlands, Texas 77381 U.S.A. (“Lexicon”), and IPSEN PHARMA SAS, a French corporation with its principal offices at 65 Quai Georges Gorse, Boulogne-Billancourt 92100, France (“Ipsen”).
